Cell-culture flu vaccines shipped from Novartis plant for 2014-5 season

By Dan Stanton contact

- Last updated on GMT

Cell-culture flu vaccine shipped from Novartis plant for 2014-5 season

Related tags: Influenza vaccine, Influenza

Novartis has shipped the first of its cell-culture - rather than chicken egg - based vaccines for the 2014-2015 flu season from its North Carolina facility.

The plant in Holly Springs, North Carolina, received a license from the US Food and Drug Administration (FDA) in June to manufacture Flucelvax and this week celebrated the first shipments of the vaccine Flucelvax from the facility for the 2014-2015 flu season with a ceremony attended by among others, Governor of North Carolina, Pat McCrory.

Flucelvax is the only flu vaccine manufactured using cell-culture technology, rather than influenza strains being grown and harvested in chicken eggs and, according to the Swiss Biopharma, is “the first major innovation in influenza vaccine production in more than 40 years.”

Furthermore, “the manufacturing process does not need advance planning, as frozen cell-culture stocks are readily available, and can be rapidly expanded to initiate production of vaccines in the event of a pandemic.”

The cell-culture-based influenza vaccine production takes place in closed and sterile bioreactors that amplify the virus production in Madin-Darby Canine Kidney (MDCK) cell lines, derived from a female cocker spaniel in 1958​.

The process consists of vaccine seed strains being provided to Novartis by the World Health Organization (WHO) from reference centres, while the MDCK cell line is grown in suspension for flu vaccine production, facilitating scalability. The virus is then propagated, purified in an automated and closed system, formulated and filled.

Novartis’ manufacturing facility comprises 44,120m2​ of space and employs 550 members of staff. It has the capability to produce 200 million adjuvanted doses of pandemic influenza vaccine within six months of the declaration of an influenza pandemic.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us


View more